MARKET

ESLA

ESLA

Estrella Immunopharma
NASDAQ
1.020
-0.030
-2.86%
Opening 10:27 03/30 EDT
OPEN
1.080
PREV CLOSE
1.050
HIGH
1.080
LOW
1.012
VOLUME
3.19K
TURNOVER
--
52 WEEK HIGH
3.150
52 WEEK LOW
0.7301
MARKET CAP
43.52M
P/E (TTM)
-2.8749
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESLA last week (0323-0327)?
Weekly Report · 4h ago
Zacks Small-Cap Research initiates coverage of Estrella Immunopharma with $12/share valuation
Reuters · 03/23 12:03
Weekly Report: what happened at ESLA last week (0316-0320)?
Weekly Report · 03/23 10:08
Estrella Immunopharma FY 2025 net loss widened 48.86% to USD 13.1 million
Reuters · 03/18 10:03
Weekly Report: what happened at ESLA last week (0309-0313)?
Weekly Report · 03/16 10:08
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/10 21:06
Weekly Report: what happened at ESLA last week (0302-0306)?
Weekly Report · 03/09 10:08
Weekly Report: what happened at ESLA last week (0223-0227)?
Weekly Report · 03/02 10:07
More
About ESLA
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

Webull offers Estrella Immunopharma Inc stock information, including NASDAQ: ESLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESLA stock methods without spending real money on the virtual paper trading platform.